Cargando…

Leucine-Rich Glioma Inactivated-1 and Voltage-Gated Potassium Channel Autoimmune Encephalitis Associated with Ischemic Stroke: A Case Report

Autoimmune encephalitis is associated with a wide variety of antibodies and clinical presentations. Voltage-gated potassium channel (VGKC) antibodies are a cause of autoimmune non-paraneoplastic encephalitis characterized by memory impairment, psychiatric symptoms, and seizures. We present a case of...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGinley, Marisa, Morales-Vidal, Sarkis, Ruland, Sean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860679/ https://www.ncbi.nlm.nih.gov/pubmed/27242653 http://dx.doi.org/10.3389/fneur.2016.00068

Ejemplares similares

Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere
por: Rachdi, Amine, et al.
Publicado: (2019)

Limbic encephalitis associated with leucine-rich glioma-inactivated 1 antibodies
por: Messelmani, Mariem, et al.
Publicado: (2015)

Anti-leucine-rich Glioma Inactivated-1 Encephalitis Associated with Essential Thrombocythemia
por: Yuan, Xiaoling, et al.
Publicado: (2020)

Autoimmune Voltage-Gated Potassium Channel Limbic Encephalitis With Auditory and Visual Hallucinations
por: Srichawla, Bahadar S
Publicado: (2022)

Leucine-rich glioma-inactivated protein 1 antibody encephalitis: A case report
por: Mayasi, Yunis, et al.
Publicado: (2014)

Motor Phenomena Associated With Leucine-Rich Glioma-Inactivated (LGI1) Emi-Encephalitis
por: Giorelli, Maurizio, et al.
Publicado: (2023)

COVID-19-Vaccine-Pfizer-BioNTech: Anti-leucine rich glioma inactivated 1 autoimmune encephalitis: case report
Publicado: (2022)

The First Case of Familiar Anti-leucine-rich Glioma-Inactivated1 Autoimmune Encephalitis: A Case Report and Literature Review
por: Ding, Chuhan, et al.
Publicado: (2022)

Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2
por: Murayama, Aki, et al.
Publicado: (2022)

A Tale of Two Brothers: Familial Voltage-Gated Potassium Channel Autoimmune Encephalitis
por: Gillespie, Lauren E, et al.
Publicado: (2020)

Reversible Bilateral Striatal Hypermetabolism in a Patient with Leucine-Rich Glioma Inactivated-1 Encephalitis
por: Takkar, Aastha, et al.
Publicado: (2016)

Morvan Syndrome Manifesting as Autoimmune Paraneoplastic Encephalitis Associated with Thymoma and Antivoltage Gated Potassium Channel (Leucine Rich, Glioma Inactivated 1) Antibody Detected using F 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2022)

CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
por: Lin, You-ting, et al.
Publicado: (2019)

Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis
por: Binks, Sophie N. M., et al.
Publicado: (2021)

Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature
por: Karvigh, Sanaz Ahmadi, et al.
Publicado: (2022)

High Grade Glioma Mimicking Voltage Gated Potassium Channel Complex Associated Antibody Limbic Encephalitis
por: Athauda, Dilan, et al.
Publicado: (2014)

Psychiatric Manifestations in an Adolescent With Voltage-Gated Potassium Channels (VGKC) Autoimmune Encephalitis: A Case Report
por: Hasan, Safa F, et al.
Publicado: (2023)

Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures
por: Li, Zhimei, et al.
Publicado: (2016)

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]
por: Wei, Mingyu, et al.
Publicado: (2020)

Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis
por: Sola-Valls, Nuria, et al.
Publicado: (2019)

Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review
por: Teng, Yuou, et al.
Publicado: (2022)

Persistent hiccup as one of the initial symptoms of leucine-rich glioma-inactivated-1 encephalitis: a case report
por: Hou, Lan, et al.
Publicado: (2022)

Anti-leucine-rich Glioma-inactivated-1 Encephalitis with Faciobrachial Dystonic Seizures and Behavioral Problems: A Case Report
por: Adhikari, Ayush, et al.
Publicado: (2020)

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]
por: Wang, Sheng-jun, et al.
Publicado: (2020)

Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis—A Pilot Study
por: Ma, Xueying, et al.
Publicado: (2020)

Serial assessment of multimodality imaging in anti-leucine-rich glioma-inactivated 1 antibody encephalitis: A case report
por: Wada, Takafumi, et al.
Publicado: (2022)

CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis
por: Li, Jinyi, et al.
Publicado: (2023)

A case of leucine-rich glioma-inactivated 1 antibody encephalitis with schizophrenia-like symptoms as an initial clinical manifestation
por: Moon, Jiyeon, et al.
Publicado: (2022)

Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine‐rich glioma‐inactivated protein 1
por: Feyissa, Anteneh M., et al.
Publicado: (2018)

Clinical characteristics of Leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 6-year-old girl: case report and literature reviews
por: Chen, Liqing, et al.
Publicado: (2023)

A Psychiatric Side Effect of Levetiracetam Can Mimic a Relapse of Anti-Leucine-Rich Glioma Inactivated 1 Encephalitis
por: Jang, Yoonhyuk, et al.
Publicado: (2018)

Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study
por: Qiao, Shan, et al.
Publicado: (2021)

Arterial Spin Labeling Imaging Characteristics of Anti-leucine-rich Glioma-Inactivated 1 Encephalitis: A Qualitative and Quantitative Analysis
por: Yedavalli, Vivek Srikar, et al.
Publicado: (2022)

Cortical metabolic characteristics of anti-leucine-rich glioma-inactivated 1 antibody encephalitis based on (18)F-FDG PET
por: Wang, Kai, et al.
Publicado: (2023)

Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia
por: Irani, Sarosh R., et al.
Publicado: (2010)

Discrimination between leucine-rich glioma-inactivated 1 antibody encephalitis and gamma-aminobutyric acid B receptor antibody encephalitis based on ResNet18
por: Pan, Jian, et al.
Publicado: (2023)

Hydrogen bonds as molecular timers for slow inactivation in voltage-gated potassium channels
por: Pless, Stephan A, et al.
Publicado: (2013)

Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma
por: Kwon, Nyoun Soo, et al.
Publicado: (2017)

Leucine-Rich Glioma-Inactivated Protein 1 Antibody-Positive Limbic Encephalitis in a Patient with Adenocarcinoma of Prostate: A Case Report
por: Navalli, Devaraddi, et al.
Publicado: (2019)

Anti-leucine-rich glioma inactivated protein 1 encephalitis with sleep disturbance as the first symptom: A case report and review of literature
por: Kong, De-Lian
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c1sntnsatebrrhbqte6erhmjf8